Thursday, April 11, 2024
Decision Reserved in Case of Ontario Doctor Who Questioned COVID Lockdowns
An Ontario doctor who was critical of COVID lockdowns argued her case in court on April 10.
Dr. Kulvinder Kaur Gill was trying to quash three cautions placed on her public file by the College of Physicians and Surgeons of Ontario (CPSO). The cautions were made after two tweets in 2020 by Dr. Gill, in which she questioned COVID lockdowns. Dr. Gill became well known during the COVID-19 pandemic for her online challenges to the government’s public health restrictions.
The panel of three judges of the Divisional Court of the Ontario Superior Court reserved their decision on the judicial review, which means there is no set date on which the decision will be released.
Dr. Gill, who specializes in pediatrics, allergy, and clinical immunology, amassed a significant following on X, formerly known as Twitter, where she expressed opinions and concerns about government’s pandemic response, including the potential negative effects of lockdowns and other mandates.
Because of that, she became the subject of seven public complaints lodged with the CPSO, along with a separate investigation by the college’s registrar.
All eight cases were reviewed by the CPSO committee known as the Inquiries, Complaints and Reports Committee (ICRC) in February 2021.
While the committee dismissed five of the complaints, it issued orders for three separate cautions to be placed on her public file.
On March 24, Elon Musk’s X announced that it would help pay her legal bills in trying to get the cautions overturned, saying in a post, “X is proud to help defend Dr. Kulvinder Kaur Gill against the government-supported efforts to cancel her speech.”
That prompted a heartfelt thank you on X from Dr. Gill: “elonmusk’s @X contacted me directly confirming Elon’s committment to pay remainder of campaign to reach $300K AND Elon has committed to assisting my appeal of 3 CPSO cautions, for my 2020 tweets opposing lockdowns, to the very end (ONCA&SCC if needed) May Waheguru bless you.”
Dr. Gill is represented by Libertas Law. In a news release from Libertas, lawyer Lisa Bildy said, “The CPSO issued guidance that doctors’ opinions during Covid-19 had to align with the government and took steps to censure ethical physicians who raised alarm bells about public health policies.”
“But the stifling of scientific debate, especially on novel measures being imposed on a massive scale, is not reasonable, in our submission, nor is it in the public interest,” Ms. Bildy continued.
The two tweets from August 2020 that were the subject of the cautions questioned if there were valid reasons for the lockdowns.
The first said, “There is absolutely no medical or scientific reason for this prolonged, harmful and illogical lockdown.”
The second tweet said, “If you have not yet figured out that we don’t need a vaccine, you are not paying attention.”
In a series of posts on X from the judicial review on April 10, JRwatch_ON said Dr. Gill’s lawyer argued that her client’s tweets were based on evidence, and that debate is important in a democratic society.
In the news release, Libertas Law said while some have portrayed Dr. Gill as an “anti-vaxxer,” it is not true.
“She has always been a proponent of routine childhood vaccines in her clinical practice,” adding that “she also supports Covid vaccines for high-risk individuals with informed consent.”
It says there was no COVID-19 vaccine authorized anywhere in the world in August 2020 when Dr. Gill posted the tweet about vaccines.
“The comment was in relation to a press conference that day by Dr. Theresa Tam in which she stated that, despite the anticipated authorization of a vaccine, possibly by that year’s end, it would not be a silver bullet and lockdowns and restrictions could persist for at least another two or three years,” said the release.
In addition, it said that “the use of widespread and prolonged lockdowns of healthy and low-risk people was contrary to all prior pandemic planning and principles of public health,” adding “evidence of lockdown harms has continued to mount.”
For its part, the CPSO has argued that the evidence indicated lockdowns in China and South Korea were having an effect, and said Dr. Gill was making misinformed and misleading statements, adding it was irresponsible to make such statements on social media during a pandemic.
The hearing is the latest in Dr. Gill’s legal battles. Last fall, she was scheduled for a disciplinary hearing by the CPSO, which was suddenly dropped in September, without the CPSO providing any specific reasons.
In a post at the start of the April 10 judicial review, Dr. Gill posted to X, “I’m at the Divisional Court of the Superior Court of Ontario today with my brilliant lawyer @LDBildy and the support of @elonmusk’s @X.”
And at the end of the hearing, Dr. Gill posted: “and that’s a wrap. A sincere thank you to all who sent their prayers & well wishes, & all who followed along the @JRwatch_ON live-tweets.”
********************************************************
High Dose Spirulina Regimen Remarkably Reduces COVID-19 Mortality, Improves Hospital Discharge Rate in 7-Day Window
A biomass of cyanobacteria, meaning blue-green algae, spirulina (arthrospira platensis), a cyanobacterium is consumed by both humans and animals, cultivated worldwide. Purported to have anti-inflammatory, antiviral and antioxidant effects, in Western society any claims must be backed by well-designed, randomized controlled trials.
The form Arthrospira is used as a dietary supplement or whole food. What’s the effect of high-dose Spirulina supplementation on hospitalized adults with COVID-19? With not a lot of research backing such a question, a Persian team of scientists affiliated with Pasteur Institute of Iran, Bahalrloo Hospital at Tehran University of Medical Sciences and even one of the scientists affiliated with Tufts University in the U.S. sought to evaluate the efficacy and safety of high-dose Spirulina platensis for SARS-CoV-2 infection.
The results are frankly remarkable, but the study has limitations—the open-label introduces the opportunity for biases, and the study size suggests the need for larger confirming studies, the results published in the Frontiers in Immunology peer-reviewed journal point to a significant finding. Western medicine would not accept these findings as particularly earth shaking but nonetheless, TrialSite points out some possibly intriguing outcomes.
Brief Background
The general class of product is used as feed supplement across aquaculture, aquariums and poultry industries. The use of this natural product started in the Americas—actually in present day Mexico by the Aztecs and other Mesoamericans until the 16th century. Upon the Spanish conquest soldiers of Cortes documented its use. Fast forward to modern day in addition to use as a supplement and for the industries mentioned above, spirulina is under investigation to address food security and malnutrition, plus as dietary support in scenarios such as space flight or even the Mars mission. With less need for land and water than livestock, the supplement represents an economical source of protein and energy.
What’s the basis for this Persian study?
In many societies, dietary supplements are reportedly helpful as supplements in response to viral infections. Take Spirulina, the filamentous, gram-negative cyanobacterium—a blue-green microalga that is a non-nitrogen-fixing photoautotroph according to the authors of this study recently published in Frontiers in Immunology.
Rich in protein (over 70%), plus vitamins, minerals (e.g., D, B12, provitamin A (beta carotene) and iron), numerous other ingredients are present such as phycocyanobilin (PCB), according to the Persian authors, which is a blue pigment protein with anti-inflammatory, anticancer and antioxidant properties.
Citing previous research, the authors of this study articulate that Spirulina consumption boosts B-group vitamins, especially B6, while decreasing interleukin-4 (IL-4) levels in persons with allergic rhinitis. But the substance also increases immunoglobulin A levels in saliva, suggesting that it could possibly enhance mucosal immunity. The supplement is also known to increase function of natural killer (NK) cells while boosting interferon-y (IFN-y) secretion, thus in aggregate overall better innate immune system health.
Finally, with a substance known as calcium spirulan (Ca-Sp) also present, the Iran-based investigators cite in vitro studies suggesting that this substance inhibits growth of select enveloped viruses, such as mumps virus, measles virus, influenza A (IAV), HIV-1, human cytomegalovirus and herpes simplex type 1. But in Western society, this is not widely touted, at least not in medical establishment circles. Evidence requires well-designed randomized studies.
Corresponding authors for this study included Seyed Ahmad Seyed Alinaghi, M.D., M.Phil, Ph.D. with Tehran University of Medical Science, Iranian Research Center for HIV/AIDs, Iranian Institute for Reduction of High-Risk Behaviors.
The Study
The Persian team designed a randomized controlled trial (IRCT20210216050373N1) investigating the research hypothesis: can high dose Spirulina supplement reduce COVID-19-related mortality or accelerate hospital discharge within seven days; secondary endpoint involved overall discharge or mortality?
This study was an open-label trial, conducted in a multi-center environment involving both Ziaeian Hospital and Baharloo Hospital, both affiliated with Tehran University of Medical Sciences. The trial site team recruited patients from July 27, 2021, through to February 17, 2022.
Importantly, the trial site team had to change the study from single-blind trial due to the patients in the Tehran hospitals not trusting the placebo, meaning recruitment was too challenging. This is why the investigators had to remove the placebo. The authors appeared to have followed good clinical practices, triggering protocol change, etc.
Randomized and controlled, the study team’s trial involved 189 patients with COVID-19, randomly assigned in a 1:1 ratio to an experimental group receiving 15.2g of Spirulina supplement plus standard of care (44 non-intensive care units and 52 ICU).
Conducted over a six-day period, the trial site team monitored immune mediators on days 1,3,5 and 7.
What were the study findings?
By day 7 of the study, no deaths associated with COVID-19 were reported in the Spirulina group. 15 deaths (15.3%) occurred in the control group. Within seven days, the Persian study team reported, “A greater number of patients discharged in the Spirulina group (97.7%) in the non-ICU compared to the control group (39.1%) (HR, 6.52; 95% CI, 3.50 to 12.17).”
The study team reports mortality was overall higher in the control group (8.7% non-ICU, 28.8% ICU) compared to the Spirulina group (non-ICU HR, 0.13; 95% CI, 0.02 to 0.97; ICU, HR, 0.16; 95% CI, 0.05 to 0.48).
Additionally, the team reports those patients in the ICU and in the Spirulina, arm evidenced “significant decrease in the levels of MIP-1α and IL-6.” Meanwhile, in those subjects in the intervention group (Spirulina) across ICU and non-ICU subgroups as intervention time increases reported IFN-y levels were significantly higher. Of course, this latter observation represents a cytokine playing a critical role in the immune response against both viral and bacterial infections, as well as in regulating immune response, inflammation and tumor surveillance.
The study authors report no presentation of side effects related to the Spirulina supplements.
Conclusion
The Persian team finds that high-dose Spirulina combined with the standard of care regimen in that part of the world targeting COVID-19 “may improve recovery and remarkably reduce mortality in hospitalized patients with COVID-19.”
Limitations
The Western medical world will not respond to this study result for a number of reasons. First, as the Persian authors self-declared, the study was not blinded, but as mentioned above, the investigators had to adjust to ensure sufficient level of recruitment.
TrialSite points out that non-blinded studies introduce several issues into interpreting the study result. From the potential of bias (selection bias, performance bias and detection bias) to placebo effect to observer bias and less objectivity, to mention some issues, blinded status becomes important for medical establishment acceptance.
Also, because use of traditional and herbal medicine is widespread among Persian (Iranian) peoples, the data obtained from follow-up post discharge can easily be unreliable. Importantly the authors point out this use of traditional and herbal medicines markedly increased during the COVID-19 pandemic. While follow-up was not part of the study protocol, the physician-scientists running this study to their credit “tried our best to follow up with patients long term.”
But many patients were not interested in follow-up post discharge due to a confluence of standard reasons one would find across much of the world.
*************************************************
Also see my other blogs. Main ones below:
http://edwatch.blogspot.com (EDUCATION WATCH)
http://antigreen.blogspot.com (GREENIE WATCH)
http://pcwatch.blogspot.com (POLITICAL CORRECTNESS WATCH)
http://australian-politics.blogspot.com (AUSTRALIAN POLITICS)
http://snorphty.blogspot.com (TONGUE-TIED)
https://immigwatch.blogspot.com (IMMIGRATION WATCH)
https://awesternheart.blogspot.com (THE PSYCHOLOGIST)
http://jonjayray.com/blogall.html More blogs
*********************************************************
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment